Objective. Management of systemic lupus erythematosus (SLE) is complex and variability in practices exists. Guidelines have been developed to help improve the management of SLE patients, but there has been no formal evaluation of these guidelines. This study aims to compare the scope, quality, and consistency of clinical practice guidelines on the diagnosis, monitoring, and treatment of patients with SLE. Methods. Electronic databases were searched up to April 2014. The Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument and textual synthesis was used to appraise and compare recommendations. Results. Nine clinical practice guidelines and 5 consensus statements were identified, which covered 7 topics: diagnosis, monitoring, treatment, neuropsychiatric SLE, lupus nephritis, antiphospholipid syndrome, and other manifestations of lupus. The methodological quality of the guidelines was variable, with the overall mean AGREE II scores ranging from 31% to 75%, out of a maximum 100%. Scores were consistently low for applicability, with only 1 guideline scoring above 50%. There was substantial variability in the treatments recommended for class II and V lupus nephritis, the recommended duration of maintenance therapy for class III/IV lupus nephritis (from 1 to 4 years), and timing of ophthalmologic examination for patients taking corticosteroids. Conclusion. Published guidelines on SLE cover a complex area of clinical care, but the methodological quality, scope, and recommendations varied substantially. Collaborative and multidisciplinary efforts to develop comprehensive, highquality evidence-based guidelines are needed to promote best treatment and health outcomes for patients with SLE.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a multisystem disease with a highly variable course. Management is complex and involves clinicians across many different specialties, with important variations in practice apparent across and within these specialties. For example, prescription of antimalarial drugs and testing for antiphospholipid antibodies are routine among rheumatologists but not among nonrheumatologists (1) . Prescribed doses for glucocorticoid regimens also differ across specialties (2) . Monitoring protocols and measures of disease activity in patients with nephritis vary among rheumatologists, with those with greater than 10 years' experience more likely to use qualitative measures (dipstick) than quantitative measures of proteinuria to guide therapy (3). Significant variation in practice is also seen within specialty groups, such as pediatric rheumatology (4) .
Clinical practice guidelines are "systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances" (5) . They need to be rigorously developed, consistent with the scientific literature, accessible, and implementable in practice (6, 7) . Given the complexity of and variation in SLE management, clinical practice guidelines may support clinical decision-making, improve care, and optimize outcomes. This review aims to compare the scope, quality, and consistency of clinical practice guidelines on the diagnosis, monitoring, and treatment of patients with SLE.
primarily on diagnosis, monitoring, and management of SLE. Non-English language publications were excluded due to lack of resources for translation. Laboratory protocols, primary research, opinions, previous guideline versions, and draft unpublished guidelines were excluded.
Search for guidelines and consensus statements. Medline, Embase, PsycINFO, and CINAHL were searched from inception to April 2014. The search strategies are provided in Supplementary Table 1 (available in the online version of this article at http://onlinelibrary.wiley.com/doi/10. 1002/acr.22591/abstract). We also searched the web sites of guideline organizations (Guidelines International Network and National Guideline Clearinghouse, Intercollegiate Guidelines Network, National Institute of Health and Care Excellence), and professional rheumatology and nephrology societies. The titles and abstracts were screened by 2 authors (DJT and AT), and those that did not meet the inclusion criteria were discarded. Full texts of the remaining citations were obtained and examined for eligibility.
Appraisal of guidelines and consensus statements. The quality of each guideline was appraised using the Appraisal of Guidelines and Research and Evaluation (AGREE) II instrument (8) . AGREE II is an internationally validated 23-item tool involving 6 domains: scope and purpose, stakeholder involvement, rigor of development, clarity and presentation, applicability, and editorial independence. Each guideline was independently appraised by 2 authors (DJT and SK), and each item within the 6 domains was rated on a Likert scale ranging from 1 to 7 (where 1 5 strongly disagree and 7 5 strongly agree). Differences in scores were resolved through discussion until consensus was reached. Domain scores were calculated as per the AGREE II user's manual, where a total quality score was obtained for each domain by summing the total item scores. The following formula was used to determine domain scores as a percentage of the total maximum score possible for that domain: domain score ¼ obtained score2minimum possible score maximum possible score2minimum possible score 3100
The maximum possible score 5 the highest possible score (i.e., 7) 3 number of items 3 number of appraisers
Significance & Innovations
Multiple clinical practice guidelines have been developed globally in the area of systemic lupus erythematosus (SLE). SLE guidelines vary in scope, methodological rigor, and recommendations based on poor-quality evidence. International collaborative multidisciplinary efforts are required for the development of high-quality guidelines. Figure 1 . Search results. * 5 other guideline organizations, i.e., SIGN, NICE and professional rheumatology and nephrology society websites; SLE 5 systemic lupus erythematosus.
(i.e., 2). The minimum possible score 5 the lowest possible score (i.e., 1) 3 number of items 3 number of appraisers (i.e., 2).
Synthesis of guideline recommendations. Textual descriptive synthesis was performed to analyze the scope (the topics covered by the guidelines), content, and consistency of recommendations across the guidelines. All text from guidelines was imported into HyperRESEARCH software for managing and retrieving textual data. One author (DJT) inductively identified topics addressed by the guidelines and coded the guideline recommendations into the corresponding topic. For each topic, the guideline recommendations were compared to identify similarities and differences.
RESULTS
Search and guideline characteristics. The search yielded 2,399 citations. Fourteen were eligible and included 9 clinical practice guidelines and 5 consensus statements ( Figure 1 ). The articles were published between 1999 and 2014, 9 from international groups and 5 from national groups. Eight guidelines were published by rheumatology societies or working groups, 1 guideline was published by a nephrology guideline organization, and 5 guidelines were published by multidisciplinary working groups. The characteristics of the guidelines are provided in Table 1 . Four guidelines (29%) conducted external peer review and 11 guidelines (79%) included a systematic literature review, although the methods of data extraction and synthesis varied (see Supplementary Table 2 , available in the online version of this article at http://onlinelibrary. wiley.com/doi/10.1002/acr.22591/abstract).
Methodological quality. Table 2 provides a summary of the results of the methodological quality appraisal. The domain scores of each guideline are displayed in Supplementary Table 3 (available in the online version of this article at http://onlinelibrary.wiley.com/doi/10.1002/acr. 22591/abstract). The highest scoring domain was scope and purpose at 67% (44-89%), and the lowest scoring domain was applicability at 29% (4-67%).
Descriptive synthesis. The 7 topics addressed by the guidelines were diagnosis, monitoring, treatment, neuropsychiatric SLE, lupus nephritis, anti-phospholipid syndrome, and other organ manifestations. The scope of the guidelines varied considerably (Supplementary Tables 4  and 5 , available in the online version of this article at http://onlinelibrary.wiley.com/doi/10.1002/acr.22591/abstract).
Diagnosis. The American College of Rheumatology (ACR) criteria for classification of patients with SLE (9) are widely used as a diagnostic aid. In patients with 4 of the 11 criteria, the diagnosis of SLE can be made with 95% specificity and 85% sensitivity (9) . One guideline specifically stated that SLE should be suspected in any patient with features affecting 2 or more organ systems listed in the ACR criteria (10).
Monitoring. Six guidelines provided recommendations on monitoring disease activity, disease damage, and quality of life (10) (11) (12) (13) (14) (15) .
Measuring disease activity with full blood count, serum creatinine, urinalysis (10) (11) (12) , and other tests, including C3/C4, anti-double-stranded DNA (anti-dsDNA), antiphospholipid, anti-RO/SSA, C-reactive protein, anti-C1q, serum albumin, estimated glomerular filtration rate (eGFR), and urinary protein:creatinine ratio, were recommended (12, 13) . The Systemic Lupus Erythrematosus Disease Activity Index was the only tool specified for adults (13) and adolescents (15) .
Annual assessment of organ damage was recommended (11, 13, 15) . The Systemic Lupus International Collaborating Clinics/ACR Damage Index was specified for use in both the adult (13) and pediatric (15) populations.
Quality of life monitoring by clinical interview and/or visual analog scale (11) or Pediatric Quality of Life Inventory Generic Core Scale, version 4.0, were suggested (15) .
Monitoring of drug toxicity was mentioned but no thresholds were provided (10, 11) . The National Cancer Institute's Common Terminology Criteria for Adverse Events, version 3.0, was recommended for use to monitor treatment side effects in pediatric SLE (15) .
Long-term monitoring was recommended (10, 14) , with 3-6 month assessment for mild disease and increased frequency for patients with severe active disease and in pregnancy (10) . Patients with nonactive SLE and no damage or comorbidity could be assessed every 6 to12 months with additional evaluation prior to pregnancy, surgery, transplantation, use of estrogen-containing medication, or occurrence of a new neurologic or vascular event (11) .
Recommendations for monitoring comorbidities were presented in 3 guidelines (11, 12, 16) . European League Against Rheumatism (EULAR) 2010 guidelines stated that all patients with SLE should be assessed for adequate calcium intake, vitamin D intake, regular exercise, smoking status, cardiovascular risk factors, blood cholesterol, glucose, body mass index, and blood pressure with no specific parameters provided (11) . Ophthalmologic examination for patients taking antimalarial medication varied; 1 guideline recommended an annual review (16) and another a 5-year review (11) ( Table 3) .
The ACR 1999 guideline advocated multidisciplinary monitoring of SLE, involving collaboration among primary care physicians, specialists, nurses, pharmacists, families, and patients (10).
Treatment. Treatment was covered by 5 guidelines. Recommendations focused on ensuring long-term survival, preventing organ damage, and improving quality of life by controlling disease activity and minimizing comorbidities and drug toxicity (14) . Treatment targets for SLE were defined as remission and prevention of flares (14), with goals defined through a shared decision-making process between the patient and clinician (14, 17) .
Recommended treatment for constitutional SLE included antimalarial drugs (10, 12, 14) , corticosteroids, and nonsteroidal antiinflammatory drugs (10, 12) . Appropriate adjunct therapy included vitamin D and calcium supple- 
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Tunnicliffe et al ments for preventing osteoporosis in patients using corticosteroids; antihypertensive drugs and statins were also recommended (12) . One guideline recommended that all patients with SLE should receive education, counselling, and support, particularly in terms of managing the complexity and unpredictability of the disease (10). Multidisciplinary care involving nephrologists, rheumatologists, and other appropriate specialists was recommended by 2 guidelines (12, 14) .
Neuropsychiatric SLE. The diagnostic workup to identify neuropsychiatric disease for patients with SLE should be the same as the general population (12, 18) . The EULAR guideline (18) provided in-depth recommendations regarding diagnosis with a diagnostic workup for acute confusional state (cerebrospinal fluid analysis and magnetic resonance imaging [MRI] ) and optic neuritis (complete ophthalmologic evaluation, MRI, and visual evoked potentials). One guideline recommended the evaluation of attention, concentration, and memory for cognitive impairment (11) .
Treatment was discussed in 4 guidelines (12, 13, 17, 18) . The use of corticosteroids and immunosuppressive therapy in neuropsychiatric SLE of inflammatory origin was recommended in both EULAR guidelines (12, 18) . For severe disease such as acute confusional state, movement disorders, myelitis, psychosis, or peripheral nephropathy induction therapy (high-dose corticosteroids and intravenous [IV] cyclophosphamide) followed with maintenance therapy with less intensive immunosuppression was recommended (18) . Manifestations, including cerebrovascular, cognitive dysfunction, seizures, and major depression should be managed the same as for the general population, with anticoagulation recommended for patients with antiphospholipid syndrome. Methylprednisone alone or in combination with immunosuppression was recommended for optic neuritis (18) . Other suggestions included rituximab for cognitive deficits, psychosis, or seizures (13) and IV immunoglobulin, immunoadsorption, or plasmapheresis for refractory disease not caused by antiphospholipid syndrome or atherosclerosis (17) .
Lupus nephritis. Twelve guidelines provided recommendations on lupus nephritis in 4 main areas.
1. Indications for renal biopsy and monitoring. Four guidelines specified indications for first renal biopsy (Table 3 ). There was variability in proteinuria thresholds for first renal biopsy; some guidelines recommended biopsy when proteinuria was $0.5 gm/24 hours with active urine sediment (19) (20) (21) . In addition, another guideline recommended biopsy when proteinuria was $1 gm/24 hours alone (21) . Monitoring C3/C4, anti-dsDNA, full blood cell count, and serum creatinine were recommended for nephritis, while other recommendations varied (Table 3) .
2. Treatment. Recommendations are summarized in Table 4 . Class II recommendations were classified by range of proteinuria by 3 guidelines (16,19,22 ), but not classified by 1 guideline (23). One guideline did not separate class V by non-nephrotic and nephrotic proteinuria and recommended that all class V be treated the same as class III and IV (16), unlike 4 other guidelines (19, 20, 22, 23 ) that recommended only class V with persistent nephrotic proteinuria be treated the same as class III and IV.
There were inconsistencies in recommendations for class III and IV induction and maintenance therapy. Three guidelines suggested a change of induction agent if there was a failure to respond by 6 months (12, 16, 20) and 2 recommended this at 3 months (21, 22) . The duration of maintenance therapy varied from 1 to 4 years (14, 16, 19, 21, 22) .
Hydroxychloroquine use in all lupus nephritis patients was recommended by 5 guidelines (16, (19) (20) (21) (22) , although 1 guideline recommended its use only in mild to moderate disease (23) . Seven guidelines (10, 15, 16, (19) (20) (21) (22) dealt with adjunct therapy for comorbidities for lupus nephritis patients, which included antihypertensives, statins, vitamin D, and calcium supplementation for bone protection and vaccination recommendations (see Supplementary  Table 6 , available in the online version of this article at http://onlinelibrary.wiley.com/doi/10.1002/acr.22591/ abstract).
Four guidelines (15, 16, 19, 21) provided definitions of partial and complete remission of lupus nephritis where serum creatinine reduction for complete remission was defined as ,1.2 mg/dl (16) or within 125% of baseline at 6-12 months after induction therapy (21) (see Supplementary Table 7 , available in the online version of this article at http://onlinelibrary.wiley.com/doi/10.1002/acr.22591/ abstract).
3. Reproductive health. Seven guidelines addressed this issue (Table 5) . Joint EULAR and European Renal Association-European Dialysis and Transplant Association recommended that pregnancy should be planned in patients with inactive lupus nephritis and urinary protein creatinine ratio ,50 mg/mmole for the preceding 6 months and preferably a GFR .50 ml/minute (19) . Other guidelines indicated that pregnancy should not occur until complete remission of lupus nephritis (20, 22) .
4. Pediatric lupus nephritis. Three guidelines addressed this issue (15, 19, 22) . Two guidelines recommended that it should be managed similarly to adult (17) ALNN ( (17) ALNN ( 1448 Tunnicliffe et al management (19, 22) , with drug doses based on patient size and GFR (22) . Coordinated transition from pediatric to adult care was recommended (19) . One guideline discussed induction therapy for proliferative lupus nephritis, with in-depth corticosteroid and immunosuppressant regimens provided; drug toxicity thresholds and monitoring tests for mycophenolate mofetil and mycophenolate sodium/acid were also provided (15) .
Antiphospholipid syndrome. The therapeutic goal was prevention of thromboembolic events (14, 17) . Low-dose aspirin was recommended as primary prevention for thrombosis (12, 19) , preeclampsia and pregnancy loss (12, 19, 21, 22) , and associated nephropathy (19, 21) , while in nephropathy antimalarial and/or antiplatelet/anticoagulation therapy could be considered (19) , with an international normalized ratio of 2-3 (22) .
Long-term anticoagulation for secondary prevention of recurrent stroke (19) or thrombosis was recommended (12, 16) . Intensive immunomodulatory therapy (high-dose glucocorticoids, IV immunoglobulins, plasmapheresis) or B cell depletion (rituximab or apheresis) were suggested for catastrophic antiphospholipid syndrome (17) .
Other manifestations of SLE. Three guidelines provided recommendations regarding other organ manifestations of SLE (13, 16, 22) . Lupus arthritis standard of care included corticosteroids, antimalarial drugs, azathioprine, and methotrexate (13, 17) . For refractory disease, mycophenolate mofetil as well as rituximab were suggested (13, 17) . Anti-interleukin 1 and anti-tumor necrosis factor antagonists were not recommended in these patients (17) .
The standard of care for hematologic manifestations of SLE included corticosteroids and azathioprine, mycophenolate, or cyclophosphamide (17) , with rituximab in refractory disease (13, 17) . Plasma exchange (18, 23) or immunoadsorption were mentioned (17), as was splenectomy in disease refractory to drug therapy (17) .
DISCUSSION
The variability in published guidelines for SLE was substantial, particularly in terms of scope and methodological rigor. Many recommendations were consistent, but major discrepancies were observed for specific clinical situations, particularly proteinuria thresholds indicating renal biopsy, treatment of class II and V nephritis, and duration of maintenance therapy.
Guideline scope varied broadly, ranging from the complete management of SLE to off-label medication use. The majority of guidelines were focused on lupus nephritis, and we speculated that this may be due to the larger body of research evidence on the treatment of lupus nephritis compared with other areas of SLE. Also, scope may have varied due to resource availability. For example, the scope of the guideline may have been narrowed to ensure the feasibility of developing high quality guidelines. Diagnosis of SLE was sparsely covered by guidelines and perhaps this is because it remains a challenging area due to the wide differential diagnoses, lack of evidence on the signs, symptoms, and biomarkers for SLE and a lack of consensus (24) (25) (26) . Guidelines rarely discussed the treatment goals of complete and/or partial remission, which are frequently reported in randomized control trials of treatment for lupus nephritis, despite there being no standardized criteria (27) . Although most guideline recommendations were formed on the basis of a systematic literature review, there were important differences in the approach to evidence appraisal and grading of recommendations. Guideline applicability was generally poor using the AGREE II instrument. For example, the target clinical context and patient population were often not specified. Also, potential barriers to guideline implementation were not identified in most guidelines. To assess barriers, we suggest using the National Institute for Clinical Studies barrier tool (28) or Barriers Identification and Mitigation tool (29) . Furthermore, criteria and frequency for auditing should be provided; for example, lupus nephritis guidelines could suggest collecting data on the indication for renal biopsy for on-going audit. While recommendations for audit were not included in many of the guidelines, we recognize that professional societies, including the ACR, have developed quality measures for the purposes of audit and performance measurement, as separate initiatives subsequent to guideline development (30) (31) (32) . Well-designed, focused guideline implementation projects with active involvement from guideline organizations are widely advocated (33) . Mold et al (34) explored adherence to national guidelines on asthma using multifaceted interventions in a cluster randomized trial, which showed facilitation of the guideline by an independent source improved adherence to recommendations compared to passive facilitation, by the provision of education and performance feedback alone (34) .
Improving guideline applicability could also be achieved by the active involvement of patient and caregivers in their development, which has been widely advocated (35) (36) (37) ), yet only 1 guideline addressed stakeholder involvement by specifically involving patients in guideline development. Active consumer engagement can be facilitated by involving more than 1 consumer in working groups or conducting stakeholder input exercises to elicit consumers' preferences and priorities (38) ; this has been successfully conducted for developing guidelines addressing other specialties, including chronic kidney disease (39) .
The recommendations on the diagnosis, monitoring, and treatment for lupus nephritis varied across guidelines and this could be due to the different populations included. For example, one guideline focused on the treatment of pediatric patients (15) , and another guideline focused on treatment of adult Asian patients (23) . These discrepancies were more apparent in areas with low-quality evidence and were therefore based on expert opinion and consensus (e.g., treatment of class II and V lupus nephritis). A challenge in developing high-quality guidelines on SLE is the lack of high-quality evidence for almost all aspects of disease except lupus nephritis. Therefore, as recommended by the Grading of Recommendations Assessment, Development and Evaluation Working Group (GRADE) (40) , suggestions for clinical care may be based on expert opinion, although the level of evidence must be explicit. In some areas, evidence was not included in guideline recommendations, e.g., IV cyclophosphamide use in induction therapy. A recent Cochrane review supports the recommendations of major lupus nephritis guidelines (19, 20, 22) , i.e., the use of either mycophenolate mofetil or low-dose cyclophosphamide in induction therapy of class III or IV lupus nephritis. However, the review suggests that mycophenolate mofetil may be a preferred first-line agent due to an overall better adverse effect profile compared to low-dose cyclophosphamide (41, 42) . Two guidelines were published after this review (14, 23) , but specific therapies for lupus nephritis induction were not covered by one (14) , while the other recommended corticosteroid and either mycophenolate mofetil or cyclophosphamide induction therapy (23) .
Some important areas of treatment, such as nonadherence, were not covered in guidelines. Rates of nonadherence in SLE have been reported as high as 76% (43) and are associated with a higher risk of flare, morbidity, hospitalization, and poor renal outcome (44) . Nonadherence to therapy as a cause of treatment failure is commonly seen in clinical practice (28) and may affect therapeutic decisions. Addressing the issue of adherence is likely to be an important part of optimizing outcomes. A number of trials are underway examining a way of measuring adherence that will help inform future guidelines (45) , while further studies are required to identify appropriate interventions for adherence in chronic disease (46) . This study is the first to systematically review the quality of clinical practice guidelines on SLE diagnosis, monitoring, and treatment. However, our study has limitations. The assessment of the guidelines is based on the reporting by guideline developers and ignores that the ACR recently decided to use GRADE methodology in all future guidelines, while the exclusion of non-English guidelines may limit the generalizability of the findings to other settings. Overall there is significant variability in existing guidelines for the management of SLE. Some of the variation is explained by the paucity of evidence in areas such as biomarkers, signs and symptoms for the monitoring and diagnosis of SLE, studies to identify the lowest "safe" dose of corticosteroids, and the duration of maintenance therapy for patients with nephritis. Furthermore, evidence-based criteria for diagnosis, SLE flare, and SLE remission need to be better defined and means of monitoring adherence would be a beneficial addition to guidelines.
Clearly a great deal of work has been done in developing the identified guidelines, but to avoid duplication of effort in the future we recommend that international collaborative multidisciplinary efforts are undertaken to ensure the development of comprehensive, high-quality evidence-
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